These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 19906035)
41. CD28 co-stimulation regulates the effect of transforming growth factor-beta1 on the proliferation of naïve CD4+ T cells. Sung JL; Lin JT; Gorham JD Int Immunopharmacol; 2003 Feb; 3(2):233-45. PubMed ID: 12586604 [TBL] [Abstract][Full Text] [Related]
42. Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donors. Reske D; Thomas AV; Petereit HF; Fink GR; Schroeter M Neuroimmunomodulation; 2009; 16(6):385-91. PubMed ID: 19609087 [TBL] [Abstract][Full Text] [Related]
43. Comparative study of the anti-inflammatory effect of two intravenous immunoglobulin preparations manufactured by different processes. Elluru S; Duong Van Huyen JP; Prost F; Delignat S; Bayry J; Ephrem A; Siberil S; Misra N; Lacroix-Desmzes S; Kazatchkine MD; Kaveri SV Immunol Lett; 2006 Sep; 107(1):58-62. PubMed ID: 16952403 [TBL] [Abstract][Full Text] [Related]
44. Immune modulating effects of intravenous immunoglobulin (IVIg) in autoimmune diseases. Mouthon L; Kaveri S; Kazatchkine M Transfus Sci; 1994 Dec; 15(4):393-408. PubMed ID: 10155557 [TBL] [Abstract][Full Text] [Related]
45. Differential modulation of cord blood and peripheral blood monocytes by intravenous immunoglobulin. Gille C; Dreschers S; Spring B; Tárnok A; Bocsi J; Poets CF; Orlikowsky TW Cytometry B Clin Cytom; 2012 Jan; 82(1):26-34. PubMed ID: 21812105 [TBL] [Abstract][Full Text] [Related]
47. Higher levels of soluble Fas ligand and transforming growth factor-β after omalizumab treatment: a case report. Kao SL; Yu HR; Kuo HC; Tsui KY; Wu CC; Chang LS; Liang CD; Chung YH; Yang KD J Microbiol Immunol Infect; 2012 Feb; 45(1):69-71. PubMed ID: 22244736 [TBL] [Abstract][Full Text] [Related]
48. [Mechanisms of immunoglobulins activity]. Kowalczyk D Pol Merkur Lekarski; 2011 Jun; 30(180):397-9. PubMed ID: 21751546 [TBL] [Abstract][Full Text] [Related]
49. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. Ballow M J Allergy Clin Immunol; 2011 Feb; 127(2):315-23; quiz 324-5. PubMed ID: 21185071 [TBL] [Abstract][Full Text] [Related]
50. B cells are resistant to immunomodulation by 'IVIg-educated' dendritic cells. Maddur MS; Hegde P; Sharma M; Kaveri SV; Bayry J Autoimmun Rev; 2011 Dec; 11(2):154-6. PubMed ID: 21864723 [TBL] [Abstract][Full Text] [Related]
51. Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction. Contini P; Ghio M; Merlo A; Brenci S; Filaci G; Indiveri F; Puppo F Hum Immunol; 2000 Dec; 61(12):1347-51. PubMed ID: 11163092 [TBL] [Abstract][Full Text] [Related]
52. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Puppo F; Contini P; Ghio M; Brenci S; Scudeletti M; Filaci G; Ferrone S; Indiveri F Int Immunol; 2000 Feb; 12(2):195-203. PubMed ID: 10653855 [TBL] [Abstract][Full Text] [Related]
53. IgG from atopic dermatitis patients induces IL-17 and IL-10 production in infant intrathymic TCD4 and TCD8 cells. Sgnotto FDR; de Oliveira MG; Lira AAL; Inoue AHS; Titz TO; Orfali RL; Bento-de-Souza L; Sato MN; Aoki V; Duarte AJS; Victor JR Int J Dermatol; 2018 Apr; 57(4):434-440. PubMed ID: 29355930 [TBL] [Abstract][Full Text] [Related]
54. IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice. Vassilev T; Mihaylova N; Voynova E; Nikolova M; Kazatchkine M; Kaveri S Clin Exp Immunol; 2006 Jul; 145(1):108-15. PubMed ID: 16792680 [TBL] [Abstract][Full Text] [Related]
55. Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg. Zhu D; Ravindranath MH; Terasaki PI; Miyazaki T; Pham T; Jucaud V Clin Exp Immunol; 2014 Aug; 177(2):464-77. PubMed ID: 24611451 [TBL] [Abstract][Full Text] [Related]
56. Modulation of lymphocyte and monocyte activity after intravenous immunoglobulin administration in vivo. Aukrust P; Müller F; Nordøy I; Haug CJ; Frøland SS Clin Exp Immunol; 1997 Jan; 107(1):50-6. PubMed ID: 9010256 [TBL] [Abstract][Full Text] [Related]
57. Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro. Ghio M; Contini P; Ottonello L; Arduino N; Gringeri A; Indiveri F; Dallegri F; Puppo F Thromb Haemost; 2003 Feb; 89(2):365-73. PubMed ID: 12574818 [TBL] [Abstract][Full Text] [Related]
58. A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis. Morandi F; Ferretti E; Bocca P; Prigione I; Raffaghello L; Pistoia V PLoS One; 2010 Jul; 5(7):e11763. PubMed ID: 20668702 [TBL] [Abstract][Full Text] [Related]
59. Soluble molecules in intravenous immunoglobulin: benefits and limitations. Azimi M; Aghamohammadi A; Ochs HD; Rezaei N Expert Rev Clin Immunol; 2016; 12(2):99-101. PubMed ID: 26648398 [TBL] [Abstract][Full Text] [Related]
60. Cell death modulation by intravenous immunoglobulin. von Gunten S; Simon HU J Clin Immunol; 2010 May; 30 Suppl 1():S24-30. PubMed ID: 20405180 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]